Nexus BioPharma Corporation entered into an agreement of merger and plan of reorganization to acquire Nexus BioPharma, Inc. in a reverse merger transaction on May 17, 2016. Under the terms of the agreement, Nexus Biopharma will issue 5.271 shares and convertible promissory notes for each share in Nexus BioPharma. The convertible promissory notes will be converted to 35 million shares of Nexus Biopharma. The agreement may be terminated by the mutual consent of Nexus Biopharma, Inc. and Nexus BioPharma Corp, failure to perform in any respect of any of its agreements, material breach of any representations, warranties or covenants. Dexter Caliso will resign as Chief Executive Officer and President and Presentacion Coranes will resign as Chief Financial Officer, Chief Accounting Officer, Secretary, and Treasurer of Nexus BioPharma. Warren Lau will be Chief Executive Officer, Chief Financial Officer, President and Secretary. The transaction is subject to the delivery of the required audited and unaudited consolidated financial statements to the Nexus Biopharma, Inc, regulatory approvals, executed resignations of all officers and directors of Nexus Biopharma, Inc. delivery of necessary document on closing by each party, approval of 80% shareholders of Nexus BioPharma Corporation. The transaction was approved by the Board of Directors of Nexus Biopharma and Nexus BioPharma Corporation. The transaction is expected to close prior to September 30, 2016. Nexus BioPharma Corporation completed the acquisition of Nexus BioPharma, Inc. in a reverse merger transaction on June 9, 2016.